IMCO

came out of OHSU’s Knight Cancer Institute in 2019. The primary objective of the Immune Monitoring and Cancer Omics labs is to provide our clients with a comprehensive offering of state-of-the-art research and CLIA assays generating data that leads to improved or new standards in patient care. We offer an end-to-end process in which we manage sample acquisition, preparation, assay execution, and data generation. All of our offerings including research assays are conducted under GLP standards and internally validated.